DGAT2 and cancer: An analysis of the cancer genome atlas (TCGA) database showed that an elevated mRNA level of DGAT1 was observed in ovarian, lung, gastric, prostate, breast, liver, head and neck, melanoma, pancreas, sarcoma, cervical, thymoma, thyroid, and renal cancers, while the DGAT2 mRNA level was upregulated in bladder, breast, head and neck, and thyroid cancers [104, 105].